Clinical trials: Negative Symptoms of Schizophrenia
Schizophrenia
Effect of Virtual Reality-based Therapy on Negative Symptoms in People with Schizophrenia
A randomised, controlled, double-blind clinical trial will be carried out to evaluate the effectiveness of a VR assisted treatment for negative symptoms in people with schizophrenia.
- Trial name
- VR-SCHIZO (NCT06588270)
- Testing
- Virtual Reality Therapy for the Negative Symptoms of Schizophrenia
- Where
- Chile
- Volunteers
- 102 people
- Sponsor
- Hospital de la Florida Dra. Eloiza Diaz
Prodromal Schizophrenia, Psychotic Disorders
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to…
- Trial name
- NCT00169988
- Testing
- risperidone, sertraline-primary
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder, Mixed Type
Online HD-tDCS Over the Left DLPFC During a Working Memory Task for Treating Negative Symptoms of Schizophrenia
In this randomized double-blind trial, the investigators aim to investigate whether online high definition transcranial direct current stimulation (HD-tDCS) over the left dorsolateral prefrontal cortex (DLPFC) during a working…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Mixed Type, Negative Symptoms in Schizophrenia
- Trial name
- NCT05582980
- Testing
- HD-tDCS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia
Schizophrenia is a major psychotic disorder that presents an enormous burden to the patients and their relatives. Despite treatment with second generation antipsychotics, negative symptoms and cognitive impairment often persist…
- Trial name
- RESIS (NCT00783120)
- Testing
- Repetitive transcranial magnetic stimulation
- Where
- 3 sites in Germany
- Volunteers
- 197 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Schizophrenia
Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms
A study to evaluate the long-term safety and tolerability of flexible doses of Lu AF11167 in patients with schizophrenia during the 24-week treatment period
- Trial name
- NCT03929497
- Testing
- Lu AF11167
- Where
- 30 sites in Bulgaria, Estonia and 5 more
- Volunteers
- 96 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
This is an extension study of A7501013 (P05771/NCT00145496) to further test the efficacy and safety of Asenapine compared with a marketed agent (olanzapine) in the treatment of patients with persistent negative symptoms of…
- Trial name
- NCT00174265
- Testing
- asenapine, olanzapine
- Volunteers
- 196 people
- Sponsor
- Organon and Co
Schizophrenia
Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817)
Treatment with conventional antipsychotics such as haloperidol has little effect or may sometimes even worsen negative symptoms (such as blunted affect, emotional withdrawal, and poor rapport) of schizophrenia.
- Trial name
- NCT00212836
- Testing
- asenapine, olanzapine
- Volunteers
- 481 people
- Sponsor
- Organon and Co
Schizophrenia Spectrum and Other Psychotic Disorders
Plan D- Vitamin D Supplementation in Psychotic Disorders
Background: Impairment in cognitive processing speed is a consistent finding in schizophrenia spectrum disorder. Vitamin D deficiency is found to be significantly associated with reduced processing speed.
- Trial name
- NCT05211635
- Testing
- Vitamin D
- Where
- Norway
- Volunteers
- 14 people
- Sponsor
- University Hospital, Akershus
Schizophrenia Negative Type
Safety and Feasibility of Nasal Delivery of Human Dental Follicle Mesenchymal Stem Cell-Derived Exosomes for Negative Symptoms in Treatment-Resistant Schizophrenia: A Pilot Study
The goal of this clinical trial is to determine the safety and feasibility of nasal delivery of human dental follicle mesenchymal stem cell-derived exosomes in the treatment of negative symptoms of treatment-resistant…
- Trial name
- NCT07485751
- Testing
- hDFSCs-Exo
- Volunteers
- 15 people
- Sponsor
- Zigong Mental Health Center
Schizophrenia; Psychosis
Brain Circuitry Therapeutics for Schizophrenia
This project is a double blind randomized clinical trials that examines the efficacy of cerebellar non invasive stimulation for apathy improvement in patients with schizophrenia
- Trial name
- ATHENA (NCT06341517)
- Testing
- iTBS
- Where
- 2 sites in Switzerland
- Volunteers
- 70 people
- Sponsor
- Indrit Begue
Schizophrenia, First-Episode
Optimization of Acute Treatment in First Episode Schizophrenia
The study is a multicenter, double-blind, randomized, parallel-group study with first episode schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with Risperidone or Haloperidol.
- Trial name
- NCT00157378
- Testing
- Risperidone, Haloperidol
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Chronic Schizophrenia
Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia
The purpose of this study is to determine whether the use of Nintendo Wii will help improve negative symptoms of Schizophrenia and quality of life of patients with chronic Schizophrenia.
- Trial name
- NCT01761383
- Testing
- Nintendo Wii video console and Nintendo Wii Fit Plus games
- Where
- Canada
- Volunteers
- 5 people
- Sponsor
- Queen's University
Schizophrenia
Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia
This study will recruit persons with schizophrenia or schizoaffective disorder and will use an oral glucose tolerance test to test the hypothesis that insulin resistance drives inflammation.
- Trial name
- NCT03818516
- Testing
- Oral Glucose Tolerance Test (OGTT)
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Emory University
Schizoaffective Disorder
Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia.
- Trial name
- SAPIN (NCT07058389)
- Testing
- 8-week outdoor physical activity program, 8-week indoor physical activity program
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Schizophrenia
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms.
- Trial name
- NCT07122895
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Early Psychosis, Delusions
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
The aim of the present single-centered pre-post study is to assess the feasibility and to investigate the putative efficacy of an emotion-oriented group intervention for patients with psychosis.
- Conditions
- Early Psychosis, Delusions, Emotional Distress, Self Esteem
- Trial name
- NCT04592042
- Testing
- Feel-Good- Group
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Philipps University Marburg
Schizophrenia
Antipsychotic Augmentation With L-Dopa
Dopamine, a chemical in the brain, has been linked to schizophrenia for a number of years. More recently, there is evidence that certain areas affected in schizophrenia (e.g.
- Trial name
- NCT01636037
- Testing
- levodopa/carbidopa (generic version of Sinemet)
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre for Addiction and Mental Health
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06980207
- Testing
- LY03017
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia and Disorders With Psychotic Features
The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms
The purpose of this study is to investigate if minocycline limits the development of negative symptoms in early psychosis and to test via what mechanism of action this change occurs.
- Trial name
- BeneMin (NCT02928965)
- Testing
- Minocycline
- Volunteers
- 207 people
- Sponsor
- University of Manchester